Frontlight ResearchEarly access
SuspendedNo phase
A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock
Key facts
- Who runs it
- CytoSorbents Europe GmbH
- Where
- Germany18 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- People taking part
- 260 people, planned
- Started
- 30 Jan 2022
- Expected to end
- May 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Cytosorb® 300 ml
- Record updated
- 5 August 2025
- Why it stopped
- Recruitment for the study is currently on hold to allow for a protocol amendment. This revision aims to align the study design with changes in clinical practice since the trial's initiation.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patients treated with standard of care (SOC) according to guidelines for sepsis/septic shock for > 6 and < 30 hours prior to randomization
- Vasoplegic septic shock*, requiring NA ≥ 0.2 µg/kg/min at the time of randomization, despite adequate fluid resuscitation to maintain MAP ≥ 65 mmHg after at least 6 hours of guideline-oriented initial therapy, including continuous NA administration
- Lactate >2 mmol/l and <8 mmol/l at baseline
- IL-6 ≥ 1000 ng/l at screening
- Minimum 18 years of age
- Provide voluntary consent to participate in the study either directly or via a legally authorized representative (LAR) or in accordance to the procedure after determination of an emergency situation according to Art. 68 (1) MDR, as applicable; (Septic shock is defined according to the SCCM / EISCM task force Sepsis-3 definition [Singer 2016])
Who cannot take part
- Patients with a steroid therapy above Cushing-threshold dose (e.g. 30 mg hydrocortisone/d or 6 mg prednisolone/d) for more than 30 days prior to baseline
- Cytokine-specific antibody therapy before inclusion
- Anticipated interruption of CytoSorb® therapy for more than 2 hours within the first 26 hours after start of intervention
- Cancer patients currently on chemotherapy with cytostatics, tyrosine kinase inhibitors, or a treatment with antibodies (e.g. PD-1-inhibitors)
- Patients with an abdominal source of infection without a source control intervention at the time of randomization OR a planned additional surgical intervention within the first 28 hours after randomization
- Conditions with a poor 90-day chance of survival because of an uncorrectable medical condition such as poorly controlled neoplasm, or other moribund end-stage disease states in which death was perceived to be imminent
- Administration of any other vasopressors than NA at time of randomization and within the first 28 hours after randomization
- Indication for va-ECMO at baseline OR a planned va-ECMO within the first 28 hours after randomization
- Acute traumatic brain injury
- Decision to limit or withdraw treatment within the study and/or observation period in the ICU
- Pregnancy / breast feeding
- Participation in another interventional study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To assess the performance of the CytoSorb® 300 mL device for shock reversal in patients with vasoplegic septic shock.
The 2 groups in the trial
- SoC+CytoSorb treatmentTreatment being tested
patients allocated to this group, will receive CytoSorb therapy in addition to the standard of care therapy according to applicable guidelines
Treatment: Cytosorb® 300 ml
- Standard of Care (SoC)No study treatment, for comparison
patients allocated to this group will receive only standard of care therapy according to applicable guidelines
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb® 300 ml Device for Shock Reversal in Patients With Vasoplegic Septic Shock
- Record updated
- 5 August 2025